Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2024-01-01 Epub Date: 2024-07-29 DOI:10.1080/14796694.2024.2373681

Umang Swami, Agnes Hong, Brandon Diessner, Christopher Young, Scott H Bunner, Bin Xie, Krishnan Ramaswamy, Benjamin Chastek, Nader El Chaar, Sumati Gupta

{"title":"Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States.","authors":"Umang Swami, Agnes Hong, Brandon Diessner, Christopher Young, Scott H Bunner, Bin Xie, Krishnan Ramaswamy, Benjamin Chastek, Nader El Chaar, Sumati Gupta","doi":"10.1080/14796694.2024.2373681","DOIUrl":null,"url":null,"abstract":"Aim: Androgen receptor pathway inhibitors (ARPIs) prolong metastasis-free survival and overall survival in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). This study aimed to evaluate real-world treatment patterns, utilization and survival outcomes in patients with nmCRPC.Patients & methods: This retrospective cohort study used Optum database electronic health records of patients with nmCRPC from 1 January 2007 to 31 December 2020 in the US.Results: Of 1955 patients, >80% received androgen-deprivation therapy (ADT) alone or ADT + first-generation nonsteroidal antiandrogen (NSAA) as first-line treatment, while only 8.24% received ADT + ARPI. ADT + ARPI remained underutilized even among those with high-risk nmCRPC. Further, ADT + NSAA had no survival benefit compared with ADT alone.Conclusion: Practice-improvement strategies are needed for treatment intensification with ARPIs for patients with nmCRPC.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11520573/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2373681","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Androgen receptor pathway inhibitors (ARPIs) prolong metastasis-free survival and overall survival in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). This study aimed to evaluate real-world treatment patterns, utilization and survival outcomes in patients with nmCRPC.Patients & methods: This retrospective cohort study used Optum database electronic health records of patients with nmCRPC from 1 January 2007 to 31 December 2020 in the US.Results: Of 1955 patients, >80% received androgen-deprivation therapy (ADT) alone or ADT + first-generation nonsteroidal antiandrogen (NSAA) as first-line treatment, while only 8.24% received ADT + ARPI. ADT + ARPI remained underutilized even among those with high-risk nmCRPC. Further, ADT + NSAA had no survival benefit compared with ADT alone.Conclusion: Practice-improvement strategies are needed for treatment intensification with ARPIs for patients with nmCRPC.

查看原文本刊更多论文

美国非转移性抗性前列腺癌患者的治疗模式和结果。

目的：雄激素受体通路抑制剂（ARPIs）可延长非转移性去势抵抗性前列腺癌（nmCRPC）患者的无转移生存期和总生存期。本研究旨在评估 nmCRPC 患者的实际治疗模式、使用情况和生存结果。患者与方法：这项回顾性队列研究使用了 Optum 数据库中 2007 年 1 月 1 日至 2020 年 12 月 31 日期间美国 nmCRPC 患者的电子健康记录。研究结果：在 1955 名患者中，超过 80% 的患者接受了雄激素剥夺疗法 (ADT) 或 ADT + 第一代非甾体抗雄激素 (NSAA) 作为一线治疗，而只有 8.24% 的患者接受了 ADT + ARPI。即使在高风险 nmCRPC 患者中，ADT + ARPI 的使用率也仍然偏低。此外，与单独使用 ADT 相比，ADT + NSAA 对患者的生存并无益处。结论：nmCRPC患者在接受ARPI强化治疗时需要改进实践策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.